30
Participants
Start Date
May 31, 2013
Primary Completion Date
March 31, 2015
Study Completion Date
March 31, 2015
AADvac1
AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.
Placebo
The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
Medizinische Universitat Wien, Vienna
Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik, Salzburg
Medizinische Universitat Graz, Graz
Lead Sponsor
Axon Neuroscience SE
INDUSTRY